Disease modifying drugs for rheumatological diseases: a brief history of everything

被引:6
|
作者
Giles, Joanna L. [1 ]
Polak, Oktawia J. [1 ]
Landon, John [1 ]
机构
[1] MicroPharm Ltd, Newcastle Emlyn, Carmarthenshire, Australia
来源
关键词
TUMOR-NECROSIS-FACTOR; JUVENILE IDIOPATHIC ARTHRITIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; ACTIVE PSORIATIC-ARTHRITIS; B-CELL DEPLETION; FREE H CHAINS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; SYNOVIAL-FLUID; FACTOR-ALPHA;
D O I
10.1016/bs.apcsb.2019.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The rheumatological diseases are a group of chronic, painful, degenerative and debilitating conditions with an increasing prevalence across the globe. The pathogenesis of these disorders is complex, overlapping and not fully understood. As such, it is difficult and time consuming to achieve correct diagnosis and complete remission for an individual patient. In this review we describe the most common forms of inflammatory arthritis and discuss how the management and treatment options for these rheumatic diseases have developed over time. We outline the successes and the limitations of current treatment regimens and discuss the economic burden of the current options. With advancements in understanding of disease mechanisms, we discuss the importance of the biologics revolution in the context of rheumatological disease and how the development of biosimilars and small molecule inhibitors will impact current treatment options in order to alleviate some of the cost burden of biological therapies. The ideal treatment strategy for the future would involve personalized and predictive medicine where by treatments can be tailored to an individual patient's needs in order to achieve fast and successful remission with no adverse events.
引用
收藏
页码:313 / 348
页数:36
相关论文
共 50 条
  • [1] Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs
    Rad, Sara Naji
    Pacheco, Paris
    Calvo, Luis
    Maung, Htet Htet
    Illyas, Wajiha
    Anand, Prachi
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] A rheumatological perspective on hypertension: a role for disease-modifying antirheumatic drugs?
    Poos, Stephen
    Hassan, Noha
    Jin, Shan
    Chuadhry, Ikhtesham
    Lo, David F.
    JOURNAL OF HYPERTENSION, 2025, 43 (02) : 359 - 360
  • [3] Antimalarial drugs in the treatment of rheumatological diseases
    Clarke, AK
    BRITISH JOURNAL OF RHEUMATOLOGY, 1998, 37 (05): : 580 - 580
  • [4] Antimalarial drugs in the treatment of rheumatological diseases
    Rynes, RI
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (07): : 799 - 805
  • [5] Laboratory screening for side effects of disease modifying antirheumatic drugs in daily rheumatological practice
    Simon, CH
    Vlieland, TPMV
    Dijkmans, BAC
    Moens, HJB
    Janssen, M
    Hazes, JMW
    Franken, HCM
    Vandenbroucke, JP
    Breedveld, FC
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1998, 27 (03) : 170 - 179
  • [6] In search of a system for everything - A brief history of everything
    Torosyan, R
    NEW IDEAS IN PSYCHOLOGY, 2001, 19 (02) : 171 - 173
  • [7] ADHERENCE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATIC DISEASES
    Pineda Sic, Rita Angelica
    de Jesus Hernandez-Galarza, Ivan
    Castro-Gonzalez, Marielva
    Angel Galarza-Delgado, Dionicio
    Angel Villarreal-Alarcon, Miguel
    Allan Uriarte Botello, Rodolfo
    Ilizaliturri Guerra, Octavio
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1681 - 1681
  • [8] A brief history of almost everything.
    Mayorga, DM
    REVISTA DE OCCIDENTE, 2005, (289) : 149 - 152
  • [9] A brief history of everything - Wilber,K
    Stokes, DM
    JOURNAL OF THE AMERICAN SOCIETY FOR PSYCHICAL RESEARCH, 1996, 90 (04): : 335 - 339
  • [10] A brief history of everything - Wilber,K
    Slaughter, RA
    FUTURES, 1996, 28 (08) : 793 - 795